Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 3/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 6/20 | 0.33 |
| ▸ | FPR1 | P21462 | 2/20 | 0.33 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31327029 | 0.89 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL854856 | 0.86 | ALDH1A1 (0.37) | P2RX7PDE7AGAASMN1; SMN2 | |
| SCHEMBL853448 | 0.84 | ALDH1A1 (0.39) | PDE7ASMN1; SMN2 | |
| SCHEMBL853226 | 0.84 | ALDH1A1 (0.39) | PDE7ASMN1; SMN2 | |
| SCHEMBL860997 | 0.83 | GAA (0.35) | SPRFPR1GAA | |
| SCHEMBL31327070 | 0.79 | KCNJ6 (0.34) | KCNJ6KCNJ5KCNJ3SMN1; SMN2 | |
| SCHEMBL31327044 | 0.78 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL15331251 | 0.75 | ALDH1A1 (0.48) | KCNJ6KCNJ5KCNJ3GAASMN1; SMN2 | |
| SCHEMBL15331248 | 0.74 | ALDH1A1 (0.39) | GAASMN1; SMN2 | |
| SCHEMBL21791520 | 0.68 | P2RX7 (0.37) | P2RX7CFTRSPRPDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2433943-B1 | Intermediates for thienopyrazole derivatives having PDE7 inhibitory activity | DAIICHI SANKYO CO LTD (JP) | 2013-09-11 | — | — | EP | claimed |
| US-20250066383-A1 | PDE 7 MODULATOR COMPOUNDS | OMEROS CORPORATION | 2025-02-27 | — | — | US | disclosed |
| US-8901315-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901315-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901315-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140073799-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| US-20140073799-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| US-20140073799-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| EP-2433943-B1 | Intermediates for thienopyrazole derivatives having PDE7 inhibitory activity | DAIICHI SANKYO CO LTD (JP) | 2013-09-11 | — | — | EP | disclosed |
| EP-2433943-B1 | Intermediates for thienopyrazole derivatives having PDE7 inhibitory activity | DAIICHI SANKYO CO LTD (JP) | 2013-09-11 | — | — | EP | disclosed |
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932250-B2 | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073799-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | PDE7A, PDE7B, PDE3B | P2RX7 148/4885CFTR 380/4885SPR 456/4885 |
| US-20110166343-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | PDE7A, PDE7B, PDE3B | P2RX7 148/4885CFTR 380/4885SPR 456/4885 |
| US-20250066383-A1 | PDE 7 MODULATOR COMPOUNDS | PDE7A, PDE3A, PDE3B | P2RX7 434/4885CFTR 1222/4885SPR 166/4885 |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | PDE7A, PDE7B, PDE3B | P2RX7 148/4885CFTR 380/4885SPR 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.